-
1.发明公开VERFAHREN ZUR SELEKTIVEN BESTIMMUNG VON BLOCKIERENDEN AUTOANTIKÖRPERN GEGEN DEN TSH-REZEPTOR 有权过程;在可TSH受体阻断抗体的选择性测定
公开(公告)号：EP1301767A2
公开(公告)日：2003-04-16
申请号：EP01956539.9
申请日：2001-07-17
发明人： COSTAGLIOLA, Sabine , VASSART, Gilbert , BERGMANN, Andreas , STRUCK, Joachim , MORGENTHALER, Nils, G.
IPC分类号： G01N1/00
CPC分类号： G01N33/76 , G01N33/564
摘要： The invention relates to a method for determining auto-antibodies (TRAb) to the TSH receptor (TSH-R), formed in a biological sample obtained from a patient. According to said method, the sample or at least one antibody fraction of the sample is reacted in a known manner in a reaction mixture in the presence of a first immunoreagent in the form of a selective competitor, with a second immunoreagent in the form of a TSH-R preparation. The selective competitor and/or the TSH-R preparation is/are, or can be labelled. The presence and/or quantity of the TRAb sought in the sample is determined by means of the bond between the TSH-R preparation and the selective competitor. According to the invention, the TSH receptor blocking auto-antibody (TBAb) is selectively determined in such a way, that the selective competitor is for the first time chosen to bond at those binding sites of the TSH-R preparation, for which said competitor competes with the TBAb that is to be determined, not however with the TSAb.
-
2.发明公开DIAGNOSE VON SEPSIS DURCH SELEKTIVE BESTIMMUNG DER KONZENTRATION DER CU/ZN SUPEROXIDDISMUTASE (CU/ZN SOD) IN PATIENTENPROBEN 有权败血症的用Cu / Zn超氧化物歧化酶的患者样品浓度（铜/锌超氧化物歧化酶）的选择性测定诊断
公开(公告)号：EP1711831A1
公开(公告)日：2006-10-18
申请号：EP05701314.6
申请日：2005-02-02
IPC分类号： G01N33/68 , G01N33/569 , C12Q1/28
CPC分类号： C12Q1/28 , G01N33/56911 , G01N33/6893 , G01N2800/26
摘要： The invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD or SOD-1) in a serum sample or plasma sample of a patient of this type is selectively determined, and quantitatively or semiquantitatively measured concentrations, which exceed a predetermined threshold value, e.g. greater than approximately 310 ng/ml, are correlated with a high risk of mortality.
-
公开(公告)号：EP2185938A1
公开(公告)日：2010-05-19
申请号：EP08785311.5
申请日：2008-08-01
发明人： BERGMANN, Andreas , STRUCK, Joachim , MORGENTHALER, Nils, G. , PAPASSOTIRIOU, Jana , BLANKENBERG, Stefan , LACKNER, Karl , RUPPRECHT, Hans , BICKEL, Christoph
IPC分类号： G01N33/74
CPC分类号： G01N33/74 , G01N33/53 , G01N2333/585 , G01N2800/323 , G01N2800/324 , G01N2800/50 , G01N2800/54
摘要： In vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with the personal cardiac risk, and the patients are allotted to one of said risk groups on the basis of their individual PCT concentrations
-
4.发明授权DIAGNOSE VON SEPSIS DURCH SELEKTIVE BESTIMMUNG DER KONZENTRATION DER CU/ZN SUPEROXIDDISMUTASE (CU/ZN SOD) IN PATIENTENPROBEN 有权败血症的用Cu / Zn超氧化物歧化酶的患者样品浓度（铜/锌超氧化物歧化酶）的选择性测定诊断
公开(公告)号：EP1711831B1
公开(公告)日：2008-04-30
申请号：EP05701314.6
申请日：2005-02-02
IPC分类号： G01N33/68 , G01N33/569 , C12Q1/28
CPC分类号： C12Q1/28 , G01N33/56911 , G01N33/6893 , G01N2800/26
-
5.发明公开IN VITRO VERFAHREN ZUR ERKENNUNG UND FRÜHERKENNUNG UND ZUR BEGLEITENDEN KONTROLLE DER THERAPIE VON ARZNEI- UND SUCHTMITTELINDUZIERTEN LEBERSCHÄDEN 有权体外方法进行检测和早期发现和治疗随附的制药的控制权，并寻求资金引起的肝损害
公开(公告)号：EP2016416A2
公开(公告)日：2009-01-21
申请号：EP07724987.8
申请日：2007-05-08
IPC分类号： G01N33/574 , G01N33/576 , G01N33/68
CPC分类号： G01N33/6893 , G01N2800/085
摘要： In vitro method for the identification and early identification and for the concomitant monitoring of the therapy and cure of in particular drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.
-
6.发明授权VERFAHREN ZUR SELEKTIVEN BESTIMMUNG VON BLOCKIERENDEN AUTOANTIKÖRPERN GEGEN DEN TSH-REZEPTOR 有权过程;在可TSH受体阻断抗体的选择性测定
公开(公告)号：EP1301767B1
公开(公告)日：2004-10-06
申请号：EP01956539.9
申请日：2001-07-17
发明人： COSTAGLIOLA, Sabine , VASSART, Gilbert , BERGMANN, Andreas , STRUCK, Joachim , MORGENTHALER, Nils, G.
IPC分类号： G01N1/00
CPC分类号： G01N33/76 , G01N33/564
摘要： The invention relates to a method for determining auto-antibodies (TRAb) to the TSH receptor (TSH-R), formed in a biological sample obtained from a patient. According to said method, the sample or at least one antibody fraction of the sample is reacted in a known manner in a reaction mixture in the presence of a first immunoreagent in the form of a selective competitor, with a second immunoreagent in the form of a TSH-R preparation. The selective competitor and/or the TSH-R preparation is/are, or can be labelled. The presence and/or quantity of the TRAb sought in the sample is determined by means of the bond between the TSH-R preparation and the selective competitor. According to the invention, the TSH receptor blocking auto-antibody (TBAb) is selectively determined in such a way, that the selective competitor is for the first time chosen to bond at those binding sites of the TSH-R preparation, for which said competitor competes with the TBAb that is to be determined, not however with the TSAb.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
